natgillin/translations-raw huggingface dataset:
Therefore, erythropoietic medicinal products, or other medicinal products that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving dexamethasone with thalidomide and its analogues.
Stoga, eritropoetski lijekovi ili drugi lijekovi mogu povećati rizik od tromboze, poput hormonske zamjenske terapije, trebaju se oprezno primjenjivati u bolesnika oboljelih od multipla mijeloma koji primaju deksametazon s talidomidom i njegovim analozima.
In post marketing experience tumour lysis syndrome (TLS) has been reported in patients with haematological malignancies following the use of dexamethasone alone or in combination with other chemotherapeutic agents.
Nakon stavljanja lijeka u promet, sindrom lize tumora (TLS, engl. tumour lysis syndrome) prijavljen je u bolesnika s hematološkim zloćudnim bolestima, nakon primjene deksametazona samog ili u kombinaciji s drugim kemoterapijskim lijekovima.
Common: Atrial fibrillation, supraventricular extrasystoles, tachycardia, palpitations;
Često: fibrilacija atrija, supraventrikularne ekstrasistole, tahikardija, palpitacije;
Patients from endemic areas (tropical and sub-tropical regions, southern Europe) should have a stool examination and if required an eradication of the parasite before initiating dexamethasone treatment.
Prije početka liječenja deksametazonom u bolesnika iz endemskih područja (tropskih i subtropskih regija, južne Europe) potrebno je provesti pregled stolice, te ako je potrebno i eradikaciju parazita.
The combination of dexamethasone with thalidomide, lenalidomide or pomalidomide (medicines to treat multiple myeloma) increases the risk of blood clots in the veins and arteries.
Kombinacija deksametazona s talidomidom, lenalidomidom ili pomalidomidom (lijekovima za liječenje multiplog mijeloma) povećava rizik od krvnih ugrušaka u venama i arterijama.
Uncommon: Hypothyroidism;
Manje često: hipotiroidizam;
Other medicines and Neofordex Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
If you stop taking Neofordex
Ako prestanete uzimati Neofordex
The dose of the anti-hypertensive treatment may have to be adjusted during the treatment with dexamethasone.
Doza antihipertenzivnog liječenja možda će se morati prilagoditi tijekom liječenja deksametazonom.
The dose of insulin, oral anti-diabetics and anti-hypertensive medicinal products may have to be increased.
Možda će biti potrebno pojačati dozu inzulina, peroralnog antidijabetika i antihipertenzivnih lijekova.
• Anticonvulsants that are hepatic enzyme inducers: carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone, due to the reduction of dexamethasone plasma levels and hence its efficacy.
• antikonvulzanti koji su induktori enzima jetre: karbamazepin, fosfenitoin, fenobarbital, fenitoin, primidon, zbog snižavanja razina deksametazona u plazmi, te time i njegove djelotvornosti.
• Erythromycin, due to increased metabolism of erythromycin in non-carriers of the CYP3A5*1 allele after dexamethasone treatment.
• eritromicina, zbog pojačanog metabolizma eritromicina u bolesnika koji nisu nosioci alela CYP3A5*1 nakon liječenja deksametazonom.
If you are elderly, some of the side effects of Neofordex may be more serious, especially thinning of the bones (osteoporosis), high blood pressure, low potassium levels, diabetes, susceptibility to infection and thinning of the skin.
Ako ste starija osoba, pojedine nuspojave lijeka Neofordex mogu biti ozbiljne, i to posebno stanjivanje kostiju (osteoporoza), visoki krvni tlak, niske razine kalija, dijabetes, sumnja na infekciju i stanjivanje kože.
What Neofordex contains - The active substance is dexamethasone.
Što Neofordex sadrži - Djelatna tvar je deksametazon.
Dexamethasone is metabolized via cytochrome P450 3A4 (CYP3A4).
Deksametazon je metaboliziran putem citokroma P450 3A4 (CYP3A4).
Common: may affect up to 1 in 10 people
Često: javljaju se u do 1 na 10 osoba
Not known: Pathological fracture, osteonecrosis, osteoporosis, tendon rupture.
Nepoznato: patološka fraktura, osteonekroza, osteoporoza, ruptura tetive.
• Topical gastro-intestinal medicinal products, antacids and activated carbon, as well as colestyramine, due to reduction of the intestinal absorption of dexamethasone.
• topikalni gastrointestinalni lijekovi, antacidi i aktivni ugljen, kao i kolestiramin, zbog smanjivanja intestinalne apsorpcije deksametazona.
If you are taking any of the following medicines, you should consult your doctor before taking Neofordex: - Anticoagulant medicines (which thin the blood) - Acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever, and other medicines to treat pain, inflammation and fever: ibuprofen, naproxen, diclofenac, meloxicam and others; - Medicines for treatment of hypertension or heart disease; - Medicines for treatment of diabetes; - Medicines for an upset stomach (for example antacids) and colestyramine (to lower cholesterol); - Medicines that reduce blood potassium levels: for example some diuretics or laxatives; - Cortisone or other corticosteroids, tetracosactide (used to test for adrenal function) or aminogluthetimide (used to treat Cushing's syndrome or breast cancer); - Antibiotics, with active substance names ending in -mycin and in -floxacin; antifungals (to treat fungal infections) with active substance names ending in -conazole or amphotericin B injection; and anti-HIV medicines with active substance names ending in -navir; - Rifampicin, rifabutin or isoniazid (used to treat tuberculosis); - Praziquantel or ivermectin (for certain worm infections); - Oestrogen hormones including the contraceptive pill and hormone replacement therapy (HRT); - Anticonvulsants (for the treatment of epilepsy) and midazolam (used as sleeping pill and for the treatment of epilepsy); - Aprepitant or fosaprepitant (for the treatment of nausea and vomiting after surgery or caused by chemotherapy [cancer treatment]); - Certain medicines to treat cancer: docetaxel, cyclophosphamide, lapatinib or methotrexate.
diklofenak, meloksikam i druge; - lijekove za liječenje hipertenzije ili bolesti srca; - lijekove za liječenje dijabetesa; - lijekove za liječenje nadraženog želuca (primjerice antacidi) i kolestiramin (za snižavanje kolesterola); - lijekove za snižavanje razina kalija u krvi: primjerice određene dijuretike ili laksative; - kortizon ili druge kortikosteroide, tetrakosaktid (koristi se za testiranje funkcije nadbubrežne žlijezde) ili aminoglutetimid (koristi se za liječenje Cushingovog sindroma ili raka dojke); - antibiotike, s nazivima djelatnih tvari koje završavaju na -micin i -floksacin; antimikotike (za liječenje gljivičnih infekcija) s nazivima djelatnih tvari koje završavaju na -konazol ili injekciju amfotericina B; i lijekove protiv HIV-a s nazivima djelatnih tvari koje završavaju na -navir; - rifampicin, rifabutin ili izoniazid (koristi se za liječenje tuberkuloze); - prazikvantel ili ivermektin (za određene infekcije uzrokovane crvima); - hormone estrogena, uključujući kontracepcijsku tabletu i hormonsku zamjensku terapiju; - antikonvulzive (za liječenje epilepsije) i midazolam (koristi se kao tableta za spavanje i za liječenje epilepsije); - aprepitant ili fosaprepitant (za liječenje mučnine i povraćanja nakon kirurškog zahvata ili uzrokovanih kemoterapijom [liječenje raka]); - određene lijekove za liječenje raka: docetaksel, ciklofosfamid, lapatinib ili metotreksat.
Repeated, daily administration of dexamethasone also leads to reduced dexamethasone plasma levels due to the induction of CYP3A4 and P-gp.
Ponovljena, dnevna primjena deksametazona također vodi do smanjenja razine deksametazona u plazmi zbog indukcije CYP3A4 i P-gp.
− if you have a viral infection, especially viral hepatitis, herpes, chickenpox or shingles,
− ako imate virusnu infekciju, posebno virusni hepatitis, herpes, vodene kozice ili herpes zoster,
− Slow wound healing, acne, thinning of the skin, bruising, red or purple discolorations on the skin
Sporo zarastanje rana, akne, stanjivanje kože, stvaranje modrica, crvena ili ljubičasta obojenja na koži
• Docetaxel and cyclophosphamide, due to reduction of their plasma levels by induction of CYP3A and P-gp.
• docetaksela i ciklofosfamida, zbog smanjivanja njihovih razina u plazmi indukcijom CYP3A i P-gp.
Individual tablets in intact packaging should be separated from the blister using the perforation, e.g. for use in multi-compartment compliance aids.
Pojedinačne tablete u neotvorenom pakiranju trebalo bi odvajati od blistera korištenjem perforacije, npr. za upotrebu u organizatorima za lijekove s pretincima.
A complete blood cell count, including white blood cell count with differential count, platelet count, haemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of dexamethasone/lenalidomide treatment and monthly thereafter to monitor for cytopenias.
Kako bi se pratile citopenije treba napraviti potpunu krvnu sliku, uključujući i broj bijelih krvnih stanica s diferencijalnim brojem, broj trombocita, hemoglobin i hematokrit, na početku liječenja, svaki tjedan tijekom prvih 8 tjedana liječenja deksametazonom/lenalidomidom, te nakon toga svaki mjesec.
− Aggression, confusion, irritability, nervousness, restlessness, altered mood;
− Agresija, smetenost, razdražljivost, nervoza, nemir, promjena raspoloženja;
Neutropenia was Grade 3 or 4 in 41.7% of patients who received Pom + LD-Dex, compared with 14.8% who received HD-Dex.
Neutropenija je bila stupnja 3 ili 4 u 41,7 % bolesnika koji su primili Pom + LD-Dex, u usporedbi s 14,8 % koji su primili HD-Dex.
Any hypokalaemia should be corrected and patients should be monitored clinically, for electrolytes and by electrocardiography.
Svaku hipokalemiju treba ispraviti a bolesnike treba klinički pratiti, razinu elektrolita i elektrokardiogram.
Uncommon: Febrile neutropenia, pancytopenia, coagulopathy.
Manje često: febrilna neutropenija, pankitopenija, koagulopatija.
In Pom + LD-Dex treated patients, thrombocytopenia was serious in 1.7% of patients, led to dose reduction in 6.3% of patients, to dose interruption in 8% of patients and to treatment discontinuation in 0.7% of patients.
U 1,7 % bolesnika koji su liječeni kombinacijom Pom + LD-Dex trombocitopenija je bila ozbiljna, dovela je do smanjenja doze u 6,3 % bolesnika, do prekida u doziranju u 8 % bolesnika te prekida liječenja u 0,7 % bolesnika.
− Muscle wasting, pain of the muscles, joints, bones or limbs;
Propadanje mišića, bol u mišićima, zglobovima, kostima ili udovima;
− Fever due to a lack of certain white blood cells, lack of all types of blood cells, diminished blood clotting, decreased magnesium or calcium levels in the blood;
Vrućica zbog nedostatka određenih bijelih krvnih stanica, nedostatak svih tipova krvnih stanica,
Neutropenia was the most frequently reported Grade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma treated with the combination of dexamethasone with pomalidomide.
Neutropenija je bila najviše prijavljivana hematološka nuspojava stupnja 3 ili 4 u bolesnika s recidivirajućim/refraktornim multiplim mijelomom liječenim kombinacijom deksametazona s pomalidomidom.
• Isoniazid, as glucocorticoids may decrease isoniazid plasma concentrations, probably due to a stimulation of hepatic metabolism of isoniazid and a reduction of glucocorticoid metabolism.
• izoniazida, jer glukokortikoidi mogu sniziti koncentracije izoniazida u plazmi, vjerojatno zbog stimulacije hepatičkog metabolizma izoniazida i smanjenja metabolizma glukokortikoida.
• Lapatinib, due to increased hepatotoxicity of lapatinib likely due to induction of CYP3A4 metabolism.
• lapatiniba, zbog povišene hepatotoksičnosti lapatiniba vjerojatno zbog indukcije metabolizma CYP3A4.
Close clinical supervision is required to avoid life-threatening reactions.
Kako bi se izbjegle reakcije opasne po život potreban je strogi klinički nadzor.
Neofordex is a medicine that contains the active substance dexamethasone.
Neofordex je lijek koji sadrži djelatnu tvar deksametazon.
− Cataract, blurred vision;
− Siva mrena, zamućeni vid;
• With medicinal products that carry a risk of Torsades de Pointes, due to increased risk of ventricular arrhythmia.
• s lijekovima koji predstavljaju rizik od Torsades de Pointes, zbog povišenog rizika od ventrikularne aritmije.
The combination of lenalidomide, thalidomide or pomalidomide with dexamethasone is associated with an increased risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma (see section 4.5).
Kombinacija lenalidomida, talidomida ili pomalidomida s deksametazonom povezuje se s povećanim rizikom od duboke venske tromboze i plućne embolije u bolesnika s multiplom mijelomom (vidjeti dio 4.5).
− Medicinal products that may increase dexamethasone plasma concentration:
− lijekovi koji mogu povećati koncentraciju deksametazona u plazmi:
Febrile neutropenia (FN) was experienced in 6.7% of patients who received Pom + LD-Dex, and in no patients who received HD-Dex.
Febrilnu neutropeniju (FN) doživjelo je 6,7 % bolesnika koji su primili Pom + LD-Dex i nijedan od onih koji su primili HD-Dex.
Concomitant administration of dexamethasone with substances that are metabolised via CYP3A4 or transported by P-gp could lead to increased clearance and decreased plasma concentrations of these substances:
Istovremena primjena deksametazona s tvarima koje se metaboliziraju putem CYP3A4 ili transportiraju putem P-gp-a može rezultirati povećanjem klirensa i smanjivanjem koncentracija sljedećih tvari u plazmi:
Each tablet contains dexamethasone acetate equivalent to 40 mg dexamethasone.
Svaka tableta sadrži deksametazonacetat u količini koja odgovara 40 mg deksametazona.
Concomitant administration of dexamethasone with inducers or inhibitors of CYP3A4 or P-gp may lead to decreased or increased plasma concentrations of dexamethasone, respectively.
Istodobna primjena deksametazona s induktorima ili inhibitorima CYP3A4 ili P-gp-a može rezultirati sniženim odnosno povećanim koncentracijama deksametazona u plazmi.
Common: Hypokalaemia, diabetes mellitus, anorexia, increased or decreased appetite, hypoalbuminaemia, fluid retention, hyperuricaemia;
Često: hipokalemija, dijabetes melitus, anoreksija, pojačani ili smanjeni apetit, hipoalbuminemija, zadržavanje tekućine, hiperuricemija;
Effects of other medicinal products on dexamethasone Dexamethasone is metabolized via cytochrome P450 3A4 (CYP3A4), and transported by the P-glycoprotein (P-gp, also known as MDR1).
Deksametazon se metabolizira putem citokroma P450 3A4 (CYP3A4), a prenosi putem P-glikoproteina (P-gp, također poznatog pod nazivom MDR1).
Do not take Neofordex
Nemojte uzimati Neofordex
• Ivermectin, due to a reduction of ivermectin plasma levels.
• ivermektina, zbog smanjivanja razina ivermektina u plazmi.
Uncommon: may affect up to 1 in 100 people
Manje često: javljaju se u do 1 na 100 osoba
Concomitant administration of erythropoietic medicinal products or previous history of deep vein thrombosis may also increase thrombotic risk in these patients.
Istodobna primjena eritropoetskih lijekova ili duboka venska tromboza u anamnezi može također povećati rizik od tromboze u ovih bolesnika.
− Medicinal products that may reduce dexamethasone plasma concentration:
− lijekovi koji mogu smanjiti koncentraciju deksametazona u plazmi:
Uncommon: Cerebrovascular accident, transient ischaemic attack, amnesia, coordination abnormal, ataxia, syncope;
Manje često: cerebrovaskularni inzult, prolazni cerebralni ishemijski napadaj, amnezija, poremećena koordinacija, ataksija, sinkopa;
Neutropenia occurred in 45.3% of relapsed and refractory multiple myeloma patients who received low dose dexamethasone plus pomalidomide (Pom + LD-Dex), and in 19.5% of patients who received high dose dexamethasone (HD-Dex).
Neutropenija se pojavila u 45,3 % bolesnika s recidivirajućim i refraktornim multiplim mijelomom koji su primili nisku dozu deksametazona s pomalidomidom (Pom + LD-Dex) te u 19,5 % bolesnika koji su primili visoku dozu deksametazona (HD-Dex).
40 mg dexamethasone.
40 mg deksametazona.
Common: Peripheral neuropathy, dizziness, psychomotor hyperactivity, disturbance in attention, memory impairment, tremor, paraesthesia, headache, ageusia, dysgeusia, somnolence, lethargy, balance impaired, dysphonia;
Poremećaji živčanog sustava Često: periferna neuropatija, omaglica, psihomotorička hiperaktivnost, poremećaj u pažnji, oštećenje pomćenja, tremor, parestezija, glavobolja, ageuzija, disgeusija, somnolencija, letargija, oštećena ravnoteža, disfonija;
The posology of anti-diabetic medicinal products may have to be adjusted during and after the treatment with dexamethasone.
Možda će biti potrebna prilagodba doziranja lijekova protiv dijabetesa tijekom i nakon liječenja deksametazonom.
Common: Pneumonia, herpes zoster, upper respiratory tract infection, lower respiratory tract infection, oral candidiasis, oral fungal infection, urinary tract infection, herpes simplex, candidal infection;
Često: pneumonija, herpes zoster, infekcija gornjeg dišnog trakta, infekcija donjeg dišnog trakta, oralna kandidijaza, oralna gljivična infekcija, infekcija urinarnog trakta, herpes simpleks, infekcija uzrokovana kandidom;
In addition, convulsions have been reported with concurrent use of dexamethasone and ciclosporin.
Nadalje, prijavljene su konvulzije kod istodobne primjene deksametazona i ciklosporina.
Neofordex administration should follow instructions for dexamethasone administration when described in the Summary of Product Characteristics of the associated treatment(s).
Pri primjeni lijeka Neofordex treba se pridržavati uputa za primjenu deksametazona kako je opisano u Sažetku opisa svojstava lijeka povezanog(ih) liječenja.
Not known: Adrenal atrophy, steroid withdrawal syndrome, adrenal insufficiency, hirsutism, menstrual irregularity.
Nepoznato: adrenalna atrofija, sindrom ustezanja steroida, adrenalna insuficijencija, hirsutizam, neredovitost mjesečnice.
In combination with thalidomide or its analogues the most serious adverse reactions were venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism, and myelosuppression, particularly neutropenia and thrombocytopenia (see section 4.4).
U kombinaciji s talidomidom ili njegovim analozima najozbiljnija nuspojava su bili venski tromboembolijski događaji, predominantno duboka venska tromboza i plućna embolija, te mijelosupresija, posebice neutropenija i trombocitopenija (vidjeti dio 4.4).
• Obligation to conduct post-authorisation measures N/A
• Obaveza provođenja mjera nakon davanja odobrenja
Uncommon: Dehydration, hypocalcaemia, hypomagnesemia; Not known: Glucose tolerance impaired, sodium retention, metabolic alkalosis.
Manje često dehidracija, hipokalcemija, hipomagnezemija; Nepoznato: narušena tolerancija glukoze, zadržavanje natrija, metabolička alkaloza.
Not known: Pancreatitis, gastrointestinal perforation, gastrointestinal haemorrhage, gastrointestinal ulcer.
Nepoznato: pankreatitis, gastrointestinalna perforacija, gastrointestinalno krvarenje, gastrointestinalni ulkus.
− Cushing's syndrome, i.e. weight gain of the trunk and face, excessive sweating, stretch marks, visible swollen capillaries (small blood vessels) and dryness of the skin, growth of extra facial hair (especially in women) and thinning of the hair;
vidljive nateknute kapilare (male krvne žile) i suhu koža, rast dodatnih dlaka na licu (posebice u žena) i stanjivanje kose;
Tablets should be kept in the blister package until administration.
Tablete je potrebno čuvati u blister pakiranju do primjene.
Tendonitis
Tendinitis
No data on male fertility are available.
Nema dostupnih podataka o plodnosti u muškaraca.
In patients with multiple myeloma, the combination of dexamethasone with thalidomide and its analogues is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) (see sections 4.5 and 4.8).
U bolesnika oboljelih od multiplog mijeloma, kombinacija deksametazona s talidomidom i njegovim analozima povezana je s povećanim rizikom od venske tromboembolije (predominatno duboke venske tromboze i pulmonalne embolije) kao i arterijske tromboembolije (predominatno infarkta miokarda i cerebrovaskularnog događaja) (vidjeti dijelove 4.5 i 4.8).
− Frequent urination;
Često mokrenje;
Neofordex 40 mg tablets
Neofordex 40 mg tablete
Neofordex contains lactose, a sugar.
Neofordex sadrži laktozu, šećer.
• Praziquantel, due to the reduction of praziquantel plasma concentrations due to an increase of its hepatic metabolism by dexamethasone, with a risk of failure of treatment.
• prazikvantela, zbog smanjenja koncentracija prazikvantela u plazmi zbog povećanja njegovog hepatičkog metabolizma deksametazonom, praćeno rizikom od neuspješnog liječenja.
During treatment, a diet low in simple sugars and high in protein should be followed due to the hyperglycaemic effect of corticosteroids and their stimulation of protein catabolism with a negative nitrogen balance.
Zbog hiperglikemijskog učinka kortikosteroida i njihove stimulacije katabolizma proteina s negativnom ravnotežom nitrogena tijekom liječenja treba se pridržavati prehrane koja je siromašna jednostavnim šećerima i bogata proteinima.
− Cough, breathing difficulties, difficulties speaking, sore throat or mouth, hoarseness, dry mouth,
− Kašalj, otežano disanje, otežan govor, bolno grlo ili usta, promuklost, suha usta, štucavica, upala sluznica;
Ciclosporin may also increase the intracellular uptake of dexamethasone.
Ciklosporin može također povisiti unos deksametazona u stanicu.
A similar incidence of high-grade neutropenia was reported in newly diagnosed patients treated with the combination of lenalidomide and dexamethasone.
Slična incidencija neutropenije visokog stupnja prijavljena je u novodijagnosticiranih bolesnika liječenih kombinacijom lenalidomida i deksametazona.
Common: Bronchitis, cough, dyspnoea, pharyngolaryngeal pain, hoarseness, hiccough.
Često: bronhitis, kašalj, dispneja, faringolaringalna bol, promuklost, štucavica.
Common: Neutropenia, anaemia, thrombocytopenia, lymphopenia, leukopenia, leukocytosis;
Često: neutropenija, anemija, trombocitopenija, limfopenija, leukopenija, leukocitoza;
Common: Vision blurred, cataract;
Često: zamućeni vid, katarakta;
Thrombocytopenia occurred in 27.0% of relapsed and refractory multiple myeloma patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocitopenija se pojavila u 27,0 % bolesnika s recidivirajućim i refraktornim multiplim mijelomom koji su primili Pom + LDDex i 26,8 % bolesnika koji su primili HD-Dex.
Common: Depression, anxiety, aggression, confusional state, irritability, nervousness, mood alteration, agitation, euphoric mood; Uncommon: Mood swings, hallucinations;
Često: depresija, anksioznost, agresija, konfuzno stanje, razdražljivost, nervoza, promjena raspoloženja, agitacija, euforično raspoloženje;
• Ciclosporin, due to a reduction of ciclosporin bioavailability and plasma levels.
• ciklosporina, zbog smanjivanja bioraspoloživosti i razina ciklosporina u plazmi.
− Muscle cramps, muscle weakness;
Mišićni grčevi, slabost mišića;
What Neofordex looks like and contents of the pack Each tablet is white, oblong in shape, with a score line on one face.
Svaka tableta je bijela, duguljastog oblika s razdjelnim urezom na jednoj strani.
• Aminogluthetimide, due to a reduction of the efficacy of dexamethasone through an increase of its hepatic metabolism.
• aminoglutetimid, zbog smanjenja djelotvornosti deksametazona kroz povećanje njegovog hepatičkog metabolizma.
− Bacterial, viral or fungal infections, including pneumonia, shingles, infections of the nose, mouth, tonsils or throat, bronchitis, herpes, bladder infection;
− Bakterijske, virusne ili gljivične infekcije, uključujući upalu pluća, herpes zoster, infekcije nosa, usta,
Hepatic impairment or renal insufficiency
Oštećenje funkcije jetre ili bubrežna insuficijencija